预约演示

更新于：2025-05-07

Berberine sulfate

硫酸氢黄连素

更新于：2025-05-07

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用方式-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构-

在研机构-

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C20H19NO8S

InChIKeyJISRTQBQFQMSLG-UHFFFAOYSA-M

CAS号633-66-9

关联

项与硫酸氢黄连素相关的临床试验

CTRI/2024/10/074604

/ Not yet recruitingN/A

AN OPEN LABEL,BALANCED, SINGLE-DOSE,MULTI-TREATMENT, TWO PERIOD,TWO-WAY CROSSOVER, COMPARATIVE ORAL BIOAVAILABILITY STUDY OF THYMOPRO 50 MG BIOSNEDS (0.001004 G THYMOQUINONE/ML), BERBERISOL 500 MG BIOSNEDS (0.010046 G BERBERINE HCL/ML),RESVERASOL 1000 MG BIOSNEDS (0.020048 G RESVERATROL/ML),BIOQUERCETIN 475 MG BIOSNEDS (0.010045 G QUERCETIN/ML) ANDBIOBUTYRIN 500 MG BIOSNEDS (0.010096 G TRIBUTYRIN/ML) MANUFACTURED BY VERDANT NATURE SP Z.O.O., WITH CONVENTIONAL RESVERATROL EXTRACT 1000 MG (2 X 500 MG CAPSULE) DISTRIBUTED BY BIOLAB, CONVENTIONAL QUERCETIN 475 MG CAPSULE DISTRIBUTED BY SWANSON HEALTH PRODUCTS, CONVENTIONAL TRIBUTYRIN 500 MG CAPSULE DISTRIBUTED BY DEVA NUTRITION, CONVENTIONAL THYMOQUINONE 50 MG CAPSULE DISTRIBUTED BY TRIQUETRA HEALTH AND CONVENTIONAL BERBERINE 500 MG CAPSULE DISTRIBUTED BY MEDFUTURE IN HEALTHY ADULT HUMAN SUBJECTS UNDER FASTING CONDITIONS - Nil

开始日期2024-10-07

申办/合作机构

Verdant Nature LLC.

NCT06782646

/ Enrolling by invitation临床2/3期

Assessing the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine Using Randomized, Placebo-controlled, Double-masked Trial

The goal of this clinical trial is to learn if berberine works to affect lipids and lipoproteins in Chinese females aged 20 to 65 years with hyperlipidaemia. The goal also includes to examine the sex-specific effect of berberine on lipids and lipoproteins. Our previous HMRF-funded randomized trial in men and prior evidence suggests berberine affects sex hormones. Given the different sex hormone profiles in men and women, the main question it aims to answer is:
• Does berberine have sex-specific lipid-modifying effects? Researchers will compare berberine to a placebo (a look-alike substance that contains no drug) to see if berberine works to affect lipids and lipoproteins.
Participants will:
* Take a baseline questionnaire
* Take berberine or a placebo every day for 12 weeks
* Take follow-up visits after 8 weeks and 12 weeks for blood sample collections and tests

开始日期2024-08-01

申办/合作机构

香港大学

CTRI/2024/06/069426

/ Not yet recruitingN/A

Single dose, crossover bioavailability study to compare the Formulation A Berberine 95 percent with Formulation B Berberine 95 percent plus Turmeric and Formulation C Berberine 70 percent with Formulation D Berberine 70 percent plus Turmeric in healthy adult human subjects. - NIL

开始日期2024-07-11

申办/合作机构-

100 项与硫酸氢黄连素相关的临床结果

登录后查看更多信息

100 项与硫酸氢黄连素相关的转化医学

登录后查看更多信息

100 项与硫酸氢黄连素相关的专利（医药）

登录后查看更多信息

141

项与硫酸氢黄连素相关的文献（医药）

2024-07-01·Journal of Biomedical Materials Research Part B: Applied Biomaterials

Construction of organ of Corti organoid to study the effects of berberine sulfate on damaged auditory cells

Article

作者: Zhang, Junming ; Liu, Li ; Shen, Rong ; Lou, Xiangxin

AbstractSensorineural hearing loss (SNHL) is mainly caused by injury or loss of hair cells (HCs) and associated spiral ganglion neurons (SGNs) in the inner ear. At present, there is still no effective treatment for SNHL in clinic. Recently, advances in organoid bring a promising prospect for research and treatment of SNHL. Meanwhile, three‐dimensional (3D) printing provides a tremendous opportunity to construct versatile organoids for tissue engineering and regenerative medicine. In this study, gelatin (Gel), sodium alginate (SA), and polyvinyl alcohol (PVA) were used to fabricate biomimetic scaffold through 3D printing. The organ of Corti derived from neonatal mice inner ear was seeded on the PVA/Gel/SA scaffold to construct organ of Corti organoid. Then, the organ of Corti organoid was used to study the potential protective effects of berberine sulfate on neomycin‐juried auditory HCs and SGNs. The results showed that the PVA/Gel/SA biomimetic 3D scaffolds had good cytocompatibilities and mechanical properties. The constructed organoid could maintain organ of Corti activity well in vitro. In addition, the injury intervention results showed that berberine sulfate could significantly inhibit neomycin‐induced HC and SGN damage. This study suggests that the fabricated organoid is highly biomimetic to the organ of Corti, which may provide an effective model for drug development, cell and gene therapy for SNHL.

2023-09-12·ACS Omega

Selection of Natural Compounds with HMGA-Interfering Activities and Cancer Cell Cytotoxicity

Article

作者: Quaglio, Deborah ; Bergamo, Alberta ; Amato, Beatrice ; Manfioletti, Guidalberto ; Sgarra, Riccardo ; Botta, Bruno ; Secco, Luca ; Covaceuszach, Sonia ; Romeo, Isabella ; Ghirga, Francesca ; Gambirasi, Marta ; Mori, Mattia

HMGA proteins are intrinsically disordered (ID) chromatin architectural factors characterized by three DNA binding domains (AT-hooks) that allow them to bind into the DNA minor groove of AT-rich stretches. HMGA are functionally involved in regulating transcription, RNA processing, DNA repair, and chromatin remodeling and dynamics. These proteins are highly expressed and play essential functions during embryonic development. They are almost undetectable in adult tissues but are re-expressed at high levels in all cancers where they are involved in neoplastic transformation and cancer progression. We focused on identifying new small molecules capable of binding into the minor groove of AT-rich DNA sequences that could compete with HMGA for DNA binding and, thus, potentially interfere with their activities. Here, a docking-based virtual screening of a unique high diversity in-house library composed of around 1000 individual natural products identified 16 natural compounds as potential minor groove binders that could inhibit the interaction between HMGA and DNA. To verify the ability of these selected compounds to compete with HMGA proteins, we screened them using electrophoretic mobility shift assays. We identified Sorocein C, a Diels-Alder (D-A)-type adducts, isolated from Sorocea ilicifolia and Sorocea bonplandii with an HMGA/DNA-displacing activity and compared its activity with that of two structurally related compounds, Sorocein A and Sorocein B. All these compounds showed a cytotoxicity effect on cancer cells, suggesting that the Sorocein-structural family may provide new and yet unexplored chemotypes for the development of minor groove binders to be evaluated as anticancer agents.

2019-02-01·Chemistry – A European Journal

Strength in Numbers: Development of a Fluorescence Sensor Array for Secondary Structures of DNA

Article

作者: Granzhan, Anton ; Xie, Xiao ; Zuffo, Michela

AbstractThe high‐throughput assessment of the secondary structures adopted by DNA oligonucleotides is currently hampered by the lack of suitable biophysical methods. Fluorescent sensors hold great potential in this respect; however, the moderate selectivity that they display for one DNA conformation over the others constitutes a major drawback to the development of accurate assays. Moreover, the use of single sensors impedes a comprehensive classification of the tested sequences. Herein, we propose to overcome these limitations through the development of a fluorescence sensor array constituted by easily accessible, commercial dyes. Multivariate analysis of the emission data matrix produced by the array allows the conformational preferences of DNA sequences of interest to be explored, either by calculating the probability of group membership in the six predefined structural categories (three G‐quadruplex groups, double‐stranded, and two groups of single‐stranded forms) or by revealing their particular structural features. The assay enables rapid screening of synthetic DNA oligonucleotides in a 96‐well plate format.

项与硫酸氢黄连素相关的新闻（医药）

2023-12-28

·PRNewswire

Hi-Tech Pharmaceuticals Introduces SLIMAGLUTIDE® - A Revolutionary Breakthrough in Weight Management and Glucagon-like Peptide-1 (GLP-1) Receptor Agonist

NORCROSS, Ga., Dec. 28, 2023 /PRNewswire/ -- Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, SLIMAGLUTIDE®. This groundbreaking supplement provides a natural and effective solution for blood sugar metabolism support and healthy weight management.* Slimaglutide® is a groundbreaking weight management supplement utilizing berberine along with 10 other Glucagon-like Peptide-1 (GLP-1) Receptor agonist and secretagogues to provide a natural and effective solution for blood sugar metabolism support, healthy weight management and at an affordable cost.* Hi-Tech's Research and Development Team spent over a year researching the active ingredients and compounds that make Slimaglutide®, a Novel and Revolutionary weight management aid that will help millions of people feel great! Hi-Tech Pharmaceuticals is a leader in phellodendron and berberine research with its Nexrutine® series of berberine extracts, which have over two decades of studies and real world results in many of Hi-Tech's branded products. Slimaglutide® utilizes a 97% pure Nexrutine®XS extract naturally derived from phellodendron bark. Slimaglutide® also uses a high grade extract called YGDPure® that has been shown to work via the GLP-1 pathway among other pathways, and in multiple clinical trials has been shown in a 45 day trial that those taking YGD had incredible results! This is just another of the amazing GLP-1 compounds found in Slimaglutide®. Consumer interest in berberine, an herbal compound extracted from various plants, has skyrocketed in popularity in the past few weeks due to increased chatter over social media platforms, such as TikTok. Hi-Tech's Nexrutine® is the most studied berberine extract used for a variety of health related issues. Berberine has been used for centuries in traditional herbalism and ayurvedic medicine; however, berberine is notoriously difficult for the body to absorb effectively and often does not yield the desired results. Hi-Tech utilizes a proprietary and clinically-studied form of berberine called Nexrutine® XS Cyclosome®, which applies cutting-edge, ultra-absorption liposome and cyclodextrin technologies to address these challenges. The second pathway Hi-Tech researchers found effective compounds are from glucose-dependent Insulinotropic polypeptide (GIP). Hi-Tech developed a proprietary extract called TwinCretin® from the Fagonia Cretia, which stimulated both GLP-1 and GIP secretion, increased cellular hormone content, and upregulated gene expression of proglucagon, GIP and prohormone convertase. The release of GLP-1 and related effects delay gastric emptying and bowel motility, and in addition, exerts pressure on the hypothalamus to alter satiety; thereby, reducing appetite and assisting in weight management. Slimaglutide® is the only omni-faceted nutraceutical on the market to attack both GLP-1 and GIP secretion and is extremely potent when it comes to weight management. "Hi-Tech is committed to delivering products found in Nature and Backed by Science®," said Jared Wheat, President and CEO of Hi-Tech. "With the launch of Slimaglutide®, consumers can experience the remarkable weight management benefits of GLP-1 receptor agonists and the power of a one-of-a kind- GIP nutraceutical." About Hi-Tech: Hi-Tech Pharmaceuticals is an enormously successful company that creates, manufactures and sells high-quality products. Hi-Tech has been able to increase its market share in the United States through the acquisition of sixteen acquisitions in recent years, which included the manufacturing bases of Synergy Nutritional Industries in 2005 and Nittany Pharmaceuticals in Pennsylvania in 2012. Hi Tech also acquired many large brands such as: APS Nutrition, ALR, FormuTech Nutrition, Sports One, Innovative Laboratories, LG Sciences, iForce Nutrition, Prime Nutrition, Top Secret Nutrition, EAS and BPI Sports. Hi-Tech's recent strategy has been, and according to its leaders will continue to be, growth through Merger and Acquisition activity. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease. Media Contact: Brandon Schopp, (770) 797-9959, 370516@email4pr.com SOURCE Hi-Tech Pharmaceuticals

并购临床结果

100 项与硫酸氢黄连素相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DDW2024	N/A	盲袢综合征	-	Berberine 400 mg	醖積簾壓鏇繭憲製顧衊(鏇艱網簾衊製顧鏇壓壓) = There was no significant difference in adverse events between BBR and RIF (12.0% vs. 9.52%, P=0.790) 選範蓋襯蓋構夢構艱觸 (淵選壓鏇餘獵製窪膚壓 )	-	2024-05-20
				Rifaximin 400 mg
NCT02548832 (CTgov)	临床3期	家族性混合型高脂血症	36	Berberine (Berberine)	鏇鹹鹹憲鏇願鏇鬱糧壓(顧鬱壓憲簾構齋獵夢餘) = 鹹獵獵襯遞簾鑰壓窪觸遞壓壓繭淵餘淵觸淵鬱 (淵範窪鹹壓壓積獵衊餘, 夢衊齋壓遞鏇餘觸網壓 ~ 艱艱網願網膚鏇餘襯鏇) 更多	-	2023-02-24
				Bezafibrate (Bezafibrate)	鏇鹹鹹憲鏇願鏇鬱糧壓(顧鬱壓憲簾構齋獵夢餘) = 製鏇餘壓鹹憲選獵膚鏇遞壓壓繭淵餘淵觸淵鬱 (淵範窪鹹壓壓積獵衊餘, 簾廠膚網糧簾廠選醖鏇 ~ 選鹽衊範範壓衊鏇築繭) 更多
ESMO2022	N/A	-	-	Berberine	餘艱廠選願淵鹽製窪蓋(鑰繭顧窪繭鹽製遞鹽餘) = 鏇簾鹹積窪鏇衊網衊積鏇餘範膚衊衊簾築構築 (廠艱製窪窪醖夢範構繭 )	-	2022-09-10
				Dapagliflozin	餘艱廠選願淵鹽製窪蓋(鑰繭顧窪繭鹽製遞鹽餘) = 壓積夢廠壓鏇憲獵願顧鏇餘範膚衊衊簾築構築 (廠艱製窪窪醖夢範構繭 )
AAI2019	N/A	类风湿关节炎	-	Berberine 1 mg/kg	鬱築衊積網簾淵製積鬱(鹽憲積選艱簾蓋積醖夢) = 簾淵鹹廠鏇製鏇壓鏇糧繭積齋繭鑰糧襯齋網鑰 (膚鹹夢淵齋鹹窪糧夢獵 )	-	2019-05-01
				berberine (Vehicle control)	鬱築衊積網簾淵製積鬱(鹽憲積選艱簾蓋積醖夢) = 齋憲鹽鏇廠蓋淵餘憲壓繭積齋繭鑰糧襯齋網鑰 (膚鹹夢淵齋鹹窪糧夢獵 )